Beam Therapeutics: Base Editing Leader With Major Catalyst Next Year [Seeking Alpha]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Seeking Alpha
asbeI covered Beam Therapeutics (NASDAQ:BEAMCo-foundedby David Liu, the Broad Institute and Harvard biochemist who also founded Editas, Beam is the leading developer of genetic therapies using base editing. Base editing is the simplest form of gene editing that changes a single DNA letter. It also has exclusive rights to prime editing technology, which can insert or delete longer DNAs.Interestingly, while prime editing is the next generation technology compared, in some respects, to even CRISPR/Cas9, Beam's current pipeline is entirely focused on base editing. It has only one clinical program, BEAM-101 for Sickle Cell Disease or SCD, and this program is all base editing. Its IND was cleared last year.Beam also licensed its base editing technology to Verve Therapeutics (VERVarticleBEAM-101 has broadly successful data in animal studies. The technology edits a certain point mutation, inducing it to cause these cells to exhibit a hereditary trait seen in certain individuals where they per
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects [Seeking Alpha]Seeking Alpha
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.MarketBeat
- Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]Yahoo! Finance
- Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- InnovationRx: Base Editing Pioneer Nicole Gaudelli Joins GV [Forbes]Forbes
BEAM
Earnings
- 2/27/24 - Beat
BEAM
Sec Filings
- 4/19/24 - Form ARS
- 4/19/24 - Form DEFA14A
- 4/19/24 - Form DEF
- BEAM's page on the SEC website